a public good project by the
Synthesis
Company
of California

© 2026

Tze‐Chiang Meng | doi.page

0 works0 citations0 h-index

Tze‐Chiang Meng

Anhui Medical University(CN)First Affiliated Hospital of Anhui Medical University(CN)

Publications by Year

Research Areas

Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Epilepsy research and treatment, Immune Response and Inflammation, Nonmelanoma Skin Cancer Studies

Most-Cited Works

→ A Controlled Trial of Early Adjunctive Treatment with Corticosteroids forPneumocystis cariniiPneumonia in the Acquired Immunodeficiency Syndrome(1990)497 cited
→ Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer(2012)221 cited
→ Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies(2007)214 cited
→ Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection(1992)193 cited
→ Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator(2001)185 cited
→ The Antiviral Activity of Toll-Like Receptor 7 and 7/8 Agonists(2008)141 cited

→ Treatment of Mycobacterium avium Complex Bacteremia in AIDS with a Four-Drug Oral Regimen(1992)

138 cited

→ An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma(2008)113 cited

→ Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial(2007)110 cited

→ Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study(2001)99 cited